Veterans Administration Medical Center
Veterans Administration Medical Center
News Article | May 8, 2017
La Jolla, Calif., May 8, 2017 - An international collaborative study led by researchers at Sanford Burnham Prebys Medical Discovery Institute (SBP), with major participation from Yokohama School of Medicine, Harvard Medical School, and UC San Diego, has identified the molecular mechanism behind lithium's effectiveness in treating bipolar disorder patients. The study, published in Proceedings of the National Academy of Sciences (PNAS), utilized human induced pluripotent stem cells (hiPS cells) to map lithium's response pathway, enabling the larger pathogenesis of bipolar disorder to be identified. These results are the first to explain the molecular basis of the disease, and may support the development of a diagnostic test for the disorder as well as predict the likelihood of patient response to lithium treatment. It may also provide the basis to discover new drugs that are safer and more effective than lithium. Bipolar disorder is a mental health condition causing extreme mood swings that include emotional highs (mania or hypomania) and lows (depression) and affects approximately 5.7 million adults in the U.S. Lithium is the first treatment explored after bipolar symptoms, but it has significant limitations. Only approximately one-third of patients respond to lithium treatment, and its effect is only found through a trial-and-error process that takes months--and sometimes years--of prescribing the drug and monitoring for response. Side effects of lithium treatment can be significant, including nausea, muscle tremors, emotional numbing, irregular heartbeat, weight gain, and birth defects, and many patients choose to stop taking the medicine as a result. "Lithium has been used to treat bipolar disorder for generations, but up until now our lack of knowledge about why the therapy does or does not work for a particular patient led to unnecessary dosing and delayed finding an effective treatment. Further, its side effects are intolerable for many patients, limiting its use and creating an urgent need for more targeted drugs with minimal risks," said Evan Snyder, M.D., Ph.D., professor and director of the Center for Stem Cells and Regenerative Medicine at SBP, and senior author of the study. "Importantly, our findings open a clear path to finding safe and effective new drugs. Equally as important, it helped give us insight into what type of mechanisms cause psychiatric problems such as these." "We realized that studying the lithium response could be used as a 'molecular can-opener' to unravel the molecular pathway of this complex disorder, that turns out not to be caused by a defect in a gene, but rather by the posttranslational regulation (phosphorylation) of the product of a gene--in this case, CRMP2, an intracellular protein that regulates neural networks," added Snyder. In hiPS cells created from lithium-responsive and non-responsive patients, researchers observed a physiological difference in the regulation of CRMP2, which rendered the protein to be in a much more inactive state in responsive patients. However, the research showed that when lithium was administered to these cells, their regulatory mechanisms were corrected, restoring normal activity of CRMP2 and correcting the underlying cause of their disorder. Thus, the study demonstrated that bipolar disorder can be rooted in physiological--not necessarily genetic--mechanisms. The insights derived from the hiPS cells were validated in actual brain specimens from patients with bipolar disorder (on and off lithium), in animal models, and in the actions of living neurons. "This 'molecular can-opener' approach--using a drug known to have a useful action without exactly knowing why--allowed us to examine and understand an underlying pathogenesis of bipolar disorder," said Snyder. "The approach may be extended to additional complex disorders and diseases for which we don't understand the underlying biology but do have drugs that may have some beneficial actions, such as depression, anxiety, schizophrenia and others in need of more effective therapies. One cannot improve a therapy until one knows what molecularly really needs to be fixed." This study was performed in collaboration with Veterans Administration Medical Center in La Jolla, University of California San Diego, Yokohama City University, Massachusetts General Hospital, Harvard Medical School, Mailman Research Center at McLean Hospital, University of Connecticut School of Medicine, University of Pittsburgh Medical Center, National Institute of Mental Health, Vala Sciences, Inc., Broad Institute of MIT and Harvard University, Dalhousie University, Beth-Israel Deaconess Medical Center, Örebro University, Janssen Research & Development Labs, Waseda University, and RIKEN . Funding was provided by the National Institutes of Health (grants RC2MH090011, R21MH093958, R33MH087896 and R01MH095088 and the Library of Integrated Network-based Cellular Signatures Program), the Viterbi Foundation Neuroscience Initiative, the Stanley Medical Research Institute, the Tau Consortium, the California Institute of Regenerative Medicine, the California Bipolar Foundation and the International Bipolar Foundation. Sanford Burnham Prebys Medical Discovery Institute (SBP) is an independent nonprofit medical research organization that conducts world-class, collaborative, biological research and translates its discoveries for the benefit of patients. SBP focuses its research on cancer, immunity, neurodegeneration, metabolic disorders and rare children's diseases. The Institute invests in talent, technology and partnerships to accelerate the translation of laboratory discoveries that will have the greatest impact on patients. Recognized for its world-class NCI-designated Cancer Center and the Conrad Prebys Center for Chemical Genomics, SBP employs about 1,100 scientists and staff in San Diego (La Jolla), Calif., and Orlando (Lake Nona), Fla. For more information, visit us at SBPdiscovery.org or on Facebook at facebook.com/SBPdiscovery and on Twitter @SBPdiscovery.
News Article | May 1, 2017
Tampa, Fla. (May 1, 2017) - At the 24rd Annual Conference of the American Society of Neural Therapy and Repair (ASNTR), held April 27-29 in Clearwater Beach, Florida, ASNTR awarded The 2017 Bernard Sanberg Memorial Award for Brain Repair to Li-Ru Zhao, PhD, MD, a tenured Associate Professor, Department of Neurosurgery, State University of New York (SUNY) Upstate Medical University and research scientist at the Syracuse (NY) Veterans Administration Medical Center. The award, presented to her on Saturday April 29, recognized her significant research contributions in acute and chronic stroke, vascular dementia, traumatic brain injury (TBI), and Alzheimer's disease. Dr. Zhao received her MD from Hebei Medical College in Shijizhaung China in 1982 and her PhD in neuroscience from the Wallenberg Neuroscience Center, Lund University, Lund, Sweden in 2004. She carried out postdoctoral work at the University of Minnesota Medical School, Minneapolis. She subsequently served as a researcher and assistant at Northwestern University, and associate professor at Louisiana State University prior to coming to SUNY Upstate Medical University and the Syracuse VA Medical Center. Dr. Zhao's extensive investigation into potential treatments for the debilitating effects of stroke includes the first demonstration of the neuroprotective properties of stem cell factor (SCF), granulocyte colony-stimulating factor (G-CSF) and SCF + G-CSF combinations in treating the effects of acute and chronic stroke. She discovered that these growth factors - naturally occurring substances capable of stimulating cellular growth, proliferation and healing - could be used alone or in combination to reduced brain damage from stroke and improve motor function. Her many studies into SCF and G-CSF used a variety of approaches, including molecular and cell biology as well as brain and cell imaging. Her contributions to Alzheimer's disease (AD) research have investigated how amyloid plaques in the brain (one of the causes thought to be behind the development of AD) might be cleared by injections of bone marrow-derived monocytes/macrophages (BMDMs) and SCF+G-CSF, all of which have been found to be low in the blood and bone marrow of AD patients. In her most recent stroke studies she is investigating Cerebral Autosomal-Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL), the most common yet rare form of hereditary stroke disorder. Using animal models, she found that neural stem cells were radically reduced in patients with CADSIL, causing cognitive impairment. Currently, there is no drug that can improve the functional or delay the progressive brain damage caused by CADASIL. Her laboratory is currently studying how the bone marrow stem cell factors (SCF and G-CSF) repair the brain in both AD and CADASIL and is working at determining how the bone marrow stem cell factors regulate neuronal process formation, synaptic generation, and stem cell growth and differentiation. "Dr. Zhao's studies have significantly advanced our understanding about the contribution of SCF and G-CSF in slowing the progression of Alzheimer's disease," said Dr. Barry J. Hoffer, MD, PhD, scientist emeritus at the National Institutes of Health and an adjunct professor at Case Western Reserve University School of Medicine. "She has also carried out exceptional service activities as a peer reviewer for grants for NIH, AHA, and Alzheimer's Association, as well as for a large number of scientific journals." According to Dr. Hoffer, she has successfully balanced her career and personal life, including raising an "exceptionally gifted" son who is currently a resident in neurosurgery at University Hospitals of Cleveland. The award Dr. Zhao received is named for Bernard Sanberg, father of Dr. Paul Sanberg (University of South Florida), a co-founder of the ASNTR. After Bernard Sanberg died of a stroke in 1999, the award bearing his name was established and is presented by the ASNTR annually to an individual who has made outstanding research contributions in the field of neural therapy and repair. The award, first presented in 2000, is presented every year at ASNTR's Annual Meeting. Recent past winners of the Bernard Sanberg Memorial Award for Brain Repair include: Mariana E. Emborg, PhD, MD, University of Wisconsin-Madison, John D. Elsworth, PhD, Yale School of Medicine, Douglas Kondziolka, MD, NYU Langone Medical Center; Mike Modo, PhD, University of Pittsburgh; Timothy Collier, PhD, Michigan State University; Donald Eugene Redmond, MD, Yale University; Shinn-Zong Lin, MD, PhD, China Medical University; Howard J. Federoff, MD, PhD, Georgetown University; Barry J. Hoffer, MD, PhD, National Institutes of Health ASNTR's 25th Annual Conference will be held April 25-29, 2018 in Clearwater Beach, Florida. For more information, email Donna Morrison email@example.com or visit the ASNTR website http://www. ASNTR is a society for basic and clinical neuroscientists using a variety of technologies to better understand how the nervous system functions and establish new procedures for its repair in response to trauma or neurodegenerative disease. Member scientists employ stem/neural cell transplantation, gene therapy, trophic factor and neuroprotective compound administration and other approaches.
News Article | June 5, 2017
JACKSONVILLE, FL--(Marketwired - June 05, 2017) - The Florida Society of Ophthalmology (FSO), the preeminent professional association for medical and osteopathic doctors who specialize in vision care, elected Krishna Kishor, M.D. as president at its annual meeting, Masters in Ophthalmology 2017, held June 2-4 in Miami, Fla. As FSO president, Kishor will help lead the nonprofit association, which represents over 500 medical doctors focused on protecting the medical and surgical specialty of ophthalmology. In addition to active participation in legislative advocacy and the dissemination of responsible information to physicians and patients throughout the state, the FSO also provides continuing medical education opportunities. Kishor is an Assistant Professor of Clinical Ophthalmology at the University of Miami/Bascom Palmer Eye Institute. In 2008, he was appointed to the Ann Bates Leach Eye Hospital and has also been at the Veterans Administration Medical Center in West Palm Beach, Fla., since 2011. Kishor received his Bachelor of Science degree from Virginia Commonwealth University, and Doctor of Medicine degree from Medical College of Virginia/VCU, where he also completed his residency. Kishor has co-authored multiple publications, book chapters, and abstracts. In 2011, he received the Michael R. Redmond, M.D. Outstanding Young Ophthalmologist Award from the FSO. The FSO also announced the elections of Darby Miller, M.D. as president-elect, Kara Cavuoto, M.D. as secretary/treasurer, Joseph Nezgoda, M.D., M.B.A. as vice president of advocacy, David Eichenbaum, M.D. as vice president of education and Stacy Kruger, M.D. as vice president of outreach. Miller is a cornea and cataract specialist and an assistant professor in the Department of Ophthalmology at the Mayo Clinic in Jacksonville. He completed his cornea fellowship at the New York Eye and Ear Infirmary and his ophthalmology residency and medical school at George Washington University Medical Center. Miller completed his internship and earned his M.S. degree at Georgetown University. He completed his M.P.H. degree at Harvard University and his undergraduate studies at the University of Kansas. In 2016, Miller received the Michael R. Redmond, M.D. Outstanding Young Ophthalmologist Leadership Award. Cavuoto is an assistant professor of clinical ophthalmology and clinical pediatrics at Bascom Palmer Eye Institute at the University of Miami Miller School of Medicine. She evaluates and treats patients with pediatric eye disorders, including amblyopia and strabismus, as well as adults with strabismus. In addition, Cavuoto serves as the director of medical student education in ophthalmology at the University of Miami. In this role, she oversees all ophthalmology clerkships and pre-clinical graduate coursework and advises University of Miami medical students applying for ophthalmology residency. Cavuoto attended both college and medical school at the University of Miami as part of the Honors Program in Medicine combined BS-MD degree program. She completed an internship in internal medicine at Jackson Memorial Hospital followed by ophthalmology residency and a pediatric ophthalmology and strabismus fellowship at Bascom Palmer Eye Institute. Nezgoda is a fellowship trained retina specialist at the Florida Eye Microsurgical Institute, Inc., in West Palm Beach. His area of focus is on the treatment of macular degeneration, diabetic retinopathy, retinal detachment, inflammatory eye disease and other diseases of the retina and vitreous. Nezgoda completed a fellowship in medical and surgical diseases at the University of California and has also been a researcher at the National Institutes of Health. An honors graduate of Georgetown University, Nezgoda attended medical school at UMDNJ-Robert Wood Johnson Medical School. While there, he received several scholarships including the Gold Humanism Honor Society. Nezgoda also received the Excellence in Teaching Award from UMDNJ-RWJMS "in honor of dedicated service to clinical skills education in the preclinical years" for being the first coordinator of the Student Teaching Elective. Nezgoda performed post-graduate training at the Albert Einstein Medical Center, the New York Eye and Ear Infirmary, and Case Western University/University Hospitals of Cleveland. Eichenbaum, who was re-elected to the same role, has been employed at Retina Vitreous Associates of Florida -- St. Petersburg, Clearwater, and Tampa -- since 2007. He is also a clinical assistant professor in the Department of Ophthalmology at the University of South Florida College of Medicine. Eichenbaum received his Bachelor of Arts and medical degrees from the University of South Florida. He completed a fellowship in vitreoretinal surgery at Tufts/Ophthalmic Consultants of Boston and has co-authored multiple research interests and articles. He is a Fellow of the American Academy of Ophthalmology. In 2015, Eichenbaum received the Michael R. Redmond, M.D. Outstanding Young Ophthalmologist Award from the FSO. Kruger, who was also re-elected to the same role, is an attending physician at Stacey J. Kruger, M.D. & Associates, P.A. in Miami, Fla. Kruger received a Bachelor of Arts degree from Washington University in St. Louis and her medical degree from S.U.N.Y. Health Science Center at Brooklyn. She completed a residency in ophthalmology at Mt. Sinai School of Medicine in New York and completed a pediatric ophthalmology fellowship at the Medical University of South Carolina. In her private practice in Miami, she offers a full range of ophthalmic and contact lens services for children and young adults, as well as adult strabismus. Kruger has also been an active board member for the For Eye Care Foundation, the charitable arm of the FSO. She was the leader of an Amblyopia Awareness Campaign in 2015 and has organized and participated at numerous vision screening events around the state. In 2016, Kruger received the James W. Clower, Jr. M.D., Community Service Award for her contributions. ABOUT THE FLORIDA SOCIETY OF OPHTHALMOLOGY The Florida Society of Ophthalmology (FSO) has a rich history of serving patients since its founding in 1939 as the Florida Society of Ophthalmology and Otolaryngology. Today, the organization represents more than 500 physician members throughout the state and is focused on advancing patient care and protecting the medical specialty of ophthalmology. For more information, please visit the FSO website at www.mdeye.org. Image Available: http://www.marketwire.com/library/MwGo/2017/5/25/11G139704/Images/Krishna_Kishor-cda38e3fcb78b364928f2fc86396ffcf.jpg Image Available: http://www.marketwire.com/library/MwGo/2017/5/25/11G139704/Images/Darby_Miller-9a4549f70f9c9d7ba2e418dffb6098b1.jpg Image Available: http://www.marketwire.com/library/MwGo/2017/5/25/11G139704/Images/Kara_Cavuoto-20493c59afbea7fd81371a71d56d0ea7.jpg Image Available: http://www.marketwire.com/library/MwGo/2017/5/25/11G139704/Images/Joseph_Nezgoda-1732d643a43aa43a92e189d9e6db2b32.jpg Image Available: http://www.marketwire.com/library/MwGo/2017/5/25/11G139704/Images/David_Eichenbaum-634edc2c50ea9093910099d4e593370a.jpg Image Available: http://www.marketwire.com/library/MwGo/2017/5/25/11G139704/Images/Stacey_Kruger-ba69bf4444f791369d783f863079b5a5.jpg
Van Vleet T.M.,Veterans Administration Medical Center |
DeGutis J.M.,Veterans Administration Medical Center
Cortex | Year: 2013
Prominent deficits in spatial attention evident in patients with hemispatial neglect are often accompanied by equally prominent deficits in non-spatial attention (e.g., poor sustained and selective attention, pronounced vigilance decrement). A number of studies now show that deficits in non-spatial attention influence spatial attention. Treatment strategies focused on improving vigilance or sustained attention may effectively remediate neglect. For example, a recent study employing Tonic and Phasic Alertness Training (TAPAT), a task that requires monitoring a constant stream of hundreds of novel scenes, demonstrated group-level (n= 12) improvements after training compared to a test-retest control group or active treatment control condition on measures of visual search, midpoint estimation and working memory (DeGutis and Van Vleet, 2010). To determine whether the modality of treatment or stimulus novelty are key factors to improving hemispatial neglect, we designed a similar continuous performance training task in which eight patients with chronic and moderate to severe neglect were challenged to rapidly and continuously discriminate a limited set of centrally presented auditory tones once a day for 9. days (36-min/day). All patients demonstrated significant improvement in several, untrained measures of spatial and non-spatial visual attention, and as a group failed to demonstrate a lateralized attention deficit 24-h post-training compared to a control group of chronic neglect patients who simply waited during the training period. The results indicate that TAPAT-related improvements in hemispatial neglect are likely due to improvements in the intrinsic regulation of supramodal, non-spatial attentional resources. © 2012.
Feng X.,University of Alabama at Birmingham |
McDonald J.M.,University of Alabama at Birmingham |
McDonald J.M.,Veterans Administration Medical Center
Annual Review of Pathology: Mechanisms of Disease | Year: 2011
The skeleton provides mechanical support for stature and locomotion, protects vital organs, and controls mineral homeostasis. A healthy skeleton must be maintained by constant bone modeling to carry out these crucial functions throughout life. Bone remodeling involves the removal of old or damaged bone by osteoclasts (bone resorption) and the subsequent replacement of new bone formed by osteoblasts (bone formation). Normal bone remodeling requires a tight coupling of bone resorption to bone formation to guarantee no alteration in bone mass or quality after each remodeling cycle. However, this important physiological process can be derailed by a variety of factors, including menopause-associated hormonal changes, age-related factors, changes in physical activity, drugs, and secondary diseases, which lead to the development of various bone disorders in both women and men. We review the major diseases of bone remodeling, emphasizing our current understanding of the underlying pathophysiological mechanisms. Copyright © 2011 by Annual Reviews. All rights reserved.
Winges K.M.,Veterans Administration Medical Center
Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society | Year: 2013
Patients with multiple sclerosis (MS) demonstrate thinning of peripapillary retinal nerve fiber layer (RNFL) and decreased macular volume as measured by optical coherence tomography (OCT). To our knowledge, there are no previous reports from a large MS OCT database with strict quality control measures that quantitate RNFL and macula in patients with relapsing-remitting multiple sclerosis. The University of California Davis OCT Reading Center gathered OCT data at baseline as part of the North American phase 3 trial of fingolimod (Gilenya). Average RNFL thickness (RNFLT) and macular volume (TMV) were measured using time domain OCT (TD-OCT). RNFL quadrants, clock hours, and macular subfields were included. With strict quality control and accounting for signal strength differences, scans were categorized as "reduced" or "not reduced" for each field, based on being less than 5th percentile for age-matched controls derived from the normative database in the scanner software. Patients were deemed "abnormal" if at least 1 eye had reduced values for a given parameter. Patients with abnormalities in corresponding RNFL and macular subfields were compared by cross-tabulation. The TD-OCT data were prospectively collected from 939 of the 1,083 trial patients, 712 of whom met all final quality and data inclusion criteria. Of the final cohort, 242 (34.0%) demonstrated reduced (less than 5th percentile) average RNFLT in at least 1 eye. One hundred seventy-eight (25.0%) patients had reduced TMV. One hundred twenty-eight (18.0%) demonstrated both reduced TMV and RNFLT in the same eye, whereas 42 (5.8%) had reduced TMV and RNFLT in both eyes. Of the 242 patients with reduced average RNFL thickness, 128 (52.9%) also had reduced TMV. Fifty patients had reduced TMV in the absence of reduced RNFLT in at least 1 eye, a cohort prevalence of 7.0%. Quadrant and subfield analysis showed a predominance of temporal and inferior RNFL thinning, with inferior macular thinning corresponding best to RNFL thinning. RNFL and macular thinning/volume loss is common at baseline in relapsing-remitting multiple sclerosis, as measured by TD-OCT. When the RNFL is thin, the macular volume is reduced in more than half of the patients. There is a population of reduced TMV without any reduction in RNFLT. Documenting the prevalence and distribution of these structural abnormalities supports recent reports and suggests new retinal areas to probe for functional vision changes in MS.
Sharma M.,Veterans Administration Medical Center
Advances in experimental medicine and biology | Year: 2013
The global rise in terrorism has increased the risk of radiological events aimed at creating chaos and destabilization, although they may cause relatively limited number of immediate casualties. We have proposed that a self-administered test would be valuable for initial triage following terrorist use of nuclear/radiological devices. The urine proteome may be a useful source of the biomarkers required for developing such a test. We have developed and extensively used a rat model to study the acute and late effect of total body (TBI) and partial body irradiation on critical organ systems. This model has proven valuable for correlating the structural and functional effects of radiation with molecular changes. Results show that nephron segments differ with regard to their sensitivity and response to ionizing radiation. The urine proteome was analyzed using LC-MS/MS at 24 h after TBI or local kidney irradiation using a 10 Gy single dose of X rays. LC-MS/MS data were analyzed and grouped under Gene Ontology categories Cellular Localization, Molecular Function and Biological Process. We observed a decrease in urine protein/creatinine ratio that corroborated with decreased spectral counts for urinary albumin and other major serum proteins. Interestingly, TBI caused greater decline in urinary albumin than local kidney irradiation. Analysis of acute-phase response proteins and markers of acute kidney injury showed increased urinary levels of cystatin superfamily proteins and alpha-1-acid glycoprotein. Among proteases and protease inhibitors, levels of Kallikrein 1-related peptidase b24, precursor and products of chymotrypsin-like activity, were noticeably increased. Among the amino acids that are susceptible to oxidation by free radicals, oxidized histidine levels were increased following irradiation. Our results suggest that proteomic analysis of early changes in urinary proteins will identify biomarkers for developing a self-administered test for radiation biodosimetry.
Levin B.E.,Veterans Administration Medical Center
Brain Research | Year: 2010
A majority of human obesity is inherited as a polygenic trait. Once obesity develops, over 90% of individuals repeatedly regain lost weight after dieting. Only surgical interventions offer long lasting weight loss. Thus, clinical data suggest that some individuals have a predisposition to develop and maintain an elevated body weight set-point once they are provided with sufficient calories to gain weight. This set-point is mediated by an integrated neural network that controls energy homeostasis. Unfortunately, currently available tools for identifying obesity-prone individuals and examining the functioning of these neural systems have insufficient resolution to identify specific neural factors that cause humans to develop and maintain the obese state. However, rodent models of polygenically inherited obesity allow us to investigate the factors that both predispose them to become obese and that prevent or enhance the development of such obesity. Maternal obesity during gestation and lactation in obesity-prone rodents enhances offspring obesity and alters their neural pathways involved in energy homeostasis regulation. Early postnatal exposure of obesity-resistant offspring to the milk of genetically obese dams alters their hypothalamic pathways involved in energy homeostasis causing them to become obese when fed a high fat diet as adults. Finally, short-term exercise begun in the early post-weaning period increases the sensitivity to the anorectic effects of leptin and protects obesity-prone offspring from becoming obese for months exercise cessation. Such studies suggest that early identification of obesity-prone humans and of the factors that can prevent them from becoming obese could provide an effective strategy for preventing the world wide epidemic of obesity. © 2010 Elsevier B.V. All rights reserved.
News Article | December 19, 2016
The International Association of HealthCare Professionals is pleased to welcome Donald R. Gore, MD, MS, to their prestigious organization with his upcoming publication in The Leading Physicians of the World. Dr. Gore is a highly-trained and qualified orthopedic surgeon with an extensive expertise in all facets of orthopedic surgery. Dr. Donald R. Gore joined the Sheboygan Orthopedic Associates in 1968, an active orthopedic practice until 2013, and is currently retired from caring for individual patients, but is available for medical legal consultations. Dr. Donald R. Gore’s career in medicine began in 1960, when he graduated with his Medical Degree from the University of Illinois, followed by an internship at Milwaukee County General Hospital. During his training, Dr. Gore was a Captain in the United States Air Force, gaining extensive training in general surgery and all aspects of orthopedic surgery. He then completed a six month biomechanic fellowship at the University of California, San Francisco. Dr. Gore was board certified in Orthopedic Surgery, and became a clinical professor at the Medical College of Wisconsin in 1980. In addition to his clinical practice, Dr. Gore was involved with teaching orthopaedic residents and medical students, and was also involved in clinical and basic research at the Medical College of Wisconsin and Wood Veterans Administration Medical Center in Wood, Wisconsin. He has authored and coauthored over 50 scientific publications, and in the later part of his career he became interested in degenerative disorders of the cervical spine. For his excellence, Dr. Gore has received a Distinguished Service Award from the Department of Orthopedic Surgery at the Medical College of Wisconsin, and a Teacher of the Year Award for Orthopedic Residents from the Medical College of Wisconsin in 1977 and 1984. He has also been recognized by the Best Doctors in America in 1996, and Who’s Who in the World in 2001. Dr. Gore was an active member of the Cervical Spine Research Society, American Medical Association, American Academy of Orthopaedic Surgeons, and over 20 other medical society memberships. Dr. Gore attributes his great success to his strong education, and the support of his family, especially his wife. In his free time, Dr. Gore enjoys fly fishing and downhill skiing. Learn more about Dr. Gore by reading his upcoming publication in The Leading Physicians of the World. FindaTopDoc.com is a hub for all things medicine, featuring detailed descriptions of medical professionals across all areas of expertise, and information on thousands of healthcare topics. Each month, millions of patients use FindaTopDoc to find a doctor nearby and instantly book an appointment online or create a review. FindaTopDoc.com features each doctor’s full professional biography highlighting their achievements, experience, patient reviews and areas of expertise. A leading provider of valuable health information that helps empower patient and doctor alike, FindaTopDoc enables readers to live a happier and healthier life. For more information about FindaTopDoc, visit http://www.findatopdoc.com
News Article | February 15, 2017
Dr. Maria A. Jalloh has joined Dentalcare Associates, a multi-specialty dental practice helping patients for nearly six decades. She joins Dr. Robert V. Scalera, Jr., Dr. Martin L. Marks, and Dr. Lara Merker. “Dr. Jalloh is a welcome addition to our practice,” said Dr. Scalera, Jr., a general dentist and director of Dentalcare Associates (567 Park Avenue, Scotch Plains). “She understands the philosophy of our office. We believe in providing healthy smiles for a lifetime. Preventive care and education are the keys to the best dental health.” Dr. Jalloh is a graduate of Rutgers University. After earning her degree from Rutgers, she studied biomedical sciences at the University of Medicine and Dentistry of New Jersey, now part of Rutgers. She went on to earn her Doctor of Dental Surgery degree at New York University College of Dentistry. At New York University, she was a member of a team, consisting of prosthodontists and biomedical engineers, researching “Osseointegration in Dental Implants.” She was awarded an Honors in Research for her contributions to the study. After dental school, Dr. Jalloh completed a general practice residency at the Veterans Administration Medical Center at Lyons, N.J. She is Invisalign certified and provides all phases of general dentistry. She is a member of the American Academy of Cosmetic Dentistry, the Academy of General Dentistry and the American Dental Association. “I am very happy to be part of such a diverse and modern practice,” Dr. Jalloh said. “I look forward to being part of the Dentalcare team and keeping many more smiles in central New Jersey healthy and bright.” All phases of dentistry are offered at Dentalcare Associates (njdentalcare.com/) in a comfortable, modern office setting. The practice provides reduced radiation digital x-rays, intro-oral imaging, computerized cavity detection and strict sterilization procedures. The practice offers dental services for all ages including exams, x-rays, cleanings, sealants, fillings, crowns, root canals, periodontal therapy, dental implants and dentures. Some of the denture services include implant overdentures, full and partial dentures, flexible partials, emergency denture replacement and relines. A lab on the premises many times offers same day denture repairs. Find out more about the practice at njdentalcare.com/